ClinVar Miner

Submissions for variant NM_000492.3(CFTR):c.31G>A (p.Val11Ile) (rs1800072)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000589079 SCV000696956 uncertain significance not provided 2017-02-21 criteria provided, single submitter clinical testing Variant summary: The CFTR c.31G>A (p.Val11Ile) variant involves the alteration of a non-conserved nucleotide. 4/5 in silico tools predict a benign outcome for this variant. This variant was found in 19/120978 control chromosomes at a frequency of 0.0001571, which does not exceed the estimated maximal expected allele frequency of a pathogenic CFTR variant (0.0129603). This variant has been reported in one patient with asthma who also carried p.M1R, in one patient with clinical features of CF, and in a chronic pancreatitis patient, all without strong evidence for causality. Due to the lack of sufficient clinical information and the absence of functional studies, the variant has currently been classified as a variant of uncertain significance (VUS) until additional information becomes available.
Invitae RCV000630460 SCV000751416 uncertain significance Cystic fibrosis 2018-02-28 criteria provided, single submitter clinical testing This sequence change replaces valine with isoleucine at codon 11 of the CFTR protein (p.Val11Ile). The valine residue is weakly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs1800072, ExAC 0.03%). This variant has been reported in an individual affected with chronic pancreatitis (PMID: 27171515), and an individual with clinical manifestations consistent with the spectrum of cystic fibrosis, but no second variant was described in this individual (PMID: 15858154). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.